Literature DB >> 24895942

Power and sample size for randomized phase III survival trials under the Weibull model.

Jianrong Wu1.   

Abstract

Two parametric tests are proposed for designing randomized two-arm phase III survival trials under the Weibull model. The properties of the two parametric tests are compared with the nonparametric log-rank test through simulation studies. Power and sample size formulas of the two parametric tests are derived. The sensitivity of sample size under misspecification of the Weibull shape parameter is also investigated. The study can be designed by planning the study duration and handling nonuniform entry and loss to follow-up under the Weibull model using either the proposed parametric tests or the well-known nonparametric log-rank test.

Entities:  

Keywords:  Log-rank test; Proportional hazards model; Randomized clinical trial; Sample size; Time-to-event; Weibull distribution

Mesh:

Year:  2015        PMID: 24895942      PMCID: PMC4624291          DOI: 10.1080/10543406.2014.919940

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  12 in total

1.  Sample size estimation for non-inferiority trials of time-to-event data.

Authors:  Adam Crisp; Paula Curtis
Journal:  Pharm Stat       Date:  2008 Oct-Dec       Impact factor: 1.894

2.  Power and sample size for survival analysis under the Weibull distribution when the whole lifespan is of interest.

Authors:  M Heo; M S Faith; D B Allison
Journal:  Mech Ageing Dev       Date:  1998-05-01       Impact factor: 5.432

3.  Sample sizes based on the log-rank statistic in complex clinical trials.

Authors:  E Lakatos
Journal:  Biometrics       Date:  1988-03       Impact factor: 2.571

4.  Planning the size and duration of a clinical trial studying the time to some critical event.

Authors:  S L George; M M Desu
Journal:  J Chronic Dis       Date:  1974-02

5.  Sample-size formula for the proportional-hazards regression model.

Authors:  D A Schoenfeld
Journal:  Biometrics       Date:  1983-06       Impact factor: 2.571

6.  Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint.

Authors:  D A Schoenfeld; J R Richter
Journal:  Biometrics       Date:  1982-03       Impact factor: 2.571

7.  Planning the duration of a comparative clinical trial with loss to follow-up and a period of continued observation.

Authors:  L V Rubinstein; M H Gail; T J Santner
Journal:  J Chronic Dis       Date:  1981

8.  Introduction to sample size determination and power analysis for clinical trials.

Authors:  J M Lachin
Journal:  Control Clin Trials       Date:  1981-06

9.  Tables of the number of patients required in clinical trials using the logrank test.

Authors:  L S Freedman
Journal:  Stat Med       Date:  1982 Apr-Jun       Impact factor: 2.373

10.  Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification.

Authors:  J M Lachin; M A Foulkes
Journal:  Biometrics       Date:  1986-09       Impact factor: 2.571

View more
  4 in total

1.  Group Sequential Design for Randomized Phase III Trials under the Weibull Model.

Authors:  Jianrong Wu; Xiaoping Xiong
Journal:  J Biopharm Stat       Date:  2014-10-16       Impact factor: 1.051

2.  Spontaneous and Immune Checkpoint Inhibitor-Induced Autoimmune Diseases: Analysis of Temporal Information by Using the Japanese Adverse Drug Event Report Database.

Authors:  Keiko Ogawa; Yoshihiro Kozuka; Hitomi Uno; Kosuke Utsumi; Osamu Noyori; Rumiko Hosoki
Journal:  Clin Drug Investig       Date:  2021-06-10       Impact factor: 2.859

3.  Are non-constant rates and non-proportional treatment effects accounted for in the design and analysis of randomised controlled trials? A review of current practice.

Authors:  Kim Jachno; Stephane Heritier; Rory Wolfe
Journal:  BMC Med Res Methodol       Date:  2019-05-16       Impact factor: 4.615

4.  Critical design considerations for time-to-event endpoints in amyotrophic lateral sclerosis clinical trials.

Authors:  Ruben P A van Eijk; Stavros Nikolakopoulos; Kit C B Roes; Bas M Middelkoop; Toby A Ferguson; Pamela J Shaw; P Nigel Leigh; Ammar Al-Chalabi; Marinus J C Eijkemans; Leonard H van den Berg
Journal:  J Neurol Neurosurg Psychiatry       Date:  2019-07-10       Impact factor: 10.154

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.